OPKO Health, Inc. (NASDAQ:OPK) Stock Has Consensus Target Price of $1.55

Shares of OPKO Health, Inc. (NASDAQ:OPK) have received a consensus rating of “Hold” from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $1.55.

Several equities research analysts have commented on OPK shares. HC Wainwright reissued a “buy” rating on shares of OPKO Health in a report on Wednesday, July 29th. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, August 13th. Finally, Zacks Research raised OPKO Health from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th.

OPKO Health Stock Performance

Shares of OPK opened at $1.57 on Friday. The company has a quick ratio of 2.93, a current ratio of 3.35 and a debt-to-equity ratio of 0.28. The business’s 50 day moving average price is $1.51 and its 200-day moving average price is $1.36. OPKO Health has a 52 week low of $0.98 and a 52 week high of $1.75. The stock has a market cap of $1.17 billion, a P/E ratio of -17.44 and a beta of 1.51.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.07. The company had revenue of $163.58 million for the quarter, compared to the consensus estimate of $131.23 million. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.19) EPS. Equities research analysts anticipate that OPKO Health will post -0.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in OPK. Squarepoint Ops LLC purchased a new stake in shares of OPKO Health during the second quarter valued at approximately $62,000. Headlands Technologies LLC raised its holdings in OPKO Health by 91.2% in the 2nd quarter. Headlands Technologies LLC now owns 107,989 shares of the biotechnology company’s stock worth $162,000 after acquiring an additional 51,509 shares during the last quarter. Two Sigma Securities LLC bought a new position in OPKO Health in the 2nd quarter valued at approximately $27,000. Van ECK Associates Corp lifted its position in OPKO Health by 174.0% in the 2nd quarter. Van ECK Associates Corp now owns 438,645 shares of the biotechnology company’s stock valued at $658,000 after acquiring an additional 278,549 shares in the last quarter. Finally, Bank of America Corp DE purchased a new stake in OPKO Health during the 2nd quarter valued at $1,194,000. Institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its diagnostics businesses, the company provides laboratory services and specialized tests intended to support the detection, diagnosis and management of disease. Its operations include BioReference Health, a clinical laboratory business serving physicians, hospitals, employers and patients, as well as the 4Kscore test, which helps assess the risk of aggressive prostate cancer.

OPKO’s pharmaceutical business develops and commercializes treatments for conditions including kidney disease, endocrine disorders and growth-related conditions.